NTRA - Natera, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
37.64
+0.30 (+0.80%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close37.34
Open37.26
Bid37.05 x 800
Ask37.61 x 1400
Day's Range37.10 - 38.25
52 Week Range12.51 - 40.92
Volume625,465
Avg. Volume705,924
Market Cap2.918B
Beta (5Y Monthly)1.33
PE Ratio (TTM)N/A
EPS (TTM)-1.84
Earnings DateNov 05, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est42.50
  • PR Newswire

    National Cancer Center Japan Launches Multi-Center Randomized Trial Using Signatera™ MRD Testing in Stage II-III Colorectal Cancer

    Today Natera, Inc. (NASDAQ: NTRA) announced an agreement with the National Cancer Center (NCC) Japan to launch the CIRCULATE-IDEA trial in Japan, a prospective, multi-center, randomized trial to investigate ctDNA-guided treatment strategies for patients with Stage II-III colon cancer, based on the results of molecular residual disease (MRD) testing with Signatera. The trial is organized by the NCC and national in scope, and it is expected to include approximately 1500 patients from over 100 cancer centers across Japan.

  • Thomson Reuters StreetEvents

    Edited Transcript of NTRA earnings conference call or presentation 6-Nov-19 9:30pm GMT

    Q3 2019 Natera Inc Earnings Call

  • Natera Announces New Early Priority Date cfDNA Patent, Files Suit Against CareDx
    PR Newswire

    Natera Announces New Early Priority Date cfDNA Patent, Files Suit Against CareDx

    Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today filed suit against CareDx for infringing its U.S. Patent 10,526,658 ("the '658 patent"). The U.S. Patent Office most recently recognized Natera's innovation in cell-free DNA (cfDNA) when it awarded the '658 patent on January 7th, 2020. The '658 patent covers cfDNA-based diagnostic methods, including those for transplant. Natera now has over 200 patents issued and pending, including more than twenty in the field of transplant.

  • Natera Launches BESPOKE CRC Study to Evaluate Outcomes in 1,000 Signatera™ Patients with Stage II-III Colorectal Cancer
    PR Newswire

    Natera Launches BESPOKE CRC Study to Evaluate Outcomes in 1,000 Signatera™ Patients with Stage II-III Colorectal Cancer

    Natera, Inc. (NASDAQ: NTRA) a global leader in cell-free DNA testing, today announced a nationwide multi-center registry study called BESPOKE CRC for patients diagnosed with Stage II-III colorectal cancer (CRC). The study's objective is to measure the clinical impact of serial blood-based testing with Signatera, Natera's personalized and tumor-informed test for molecular residual disease (MRD) assessment, earlier relapse detection, and better patient risk stratification after surgery.

  • Natera To Webcast Live Presentation at the 38th Annual J.P. Morgan Healthcare Conference
    PR Newswire

    Natera To Webcast Live Presentation at the 38th Annual J.P. Morgan Healthcare Conference

    Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will webcast a live presentation at the 38th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco on Wednesday, Jan. 15, 2020 at 10:00 a.m. PT (1:00 p.m. ET).

  • Natera Announces Achievement of $55 Million In Pharma Contracts and Issuance of New Oncology Patents
    PR Newswire

    Natera Announces Achievement of $55 Million In Pharma Contracts and Issuance of New Oncology Patents

    Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced it has exceeded its 2019 goal of $40-$50 million in cumulative total contract value (TCV) and has expanded its personalized ctDNA minimal residual disease (MRD) and monitoring intellectual property portfolio with 8 newly allowed or issued patents in 2019.

  • Natera Receives Final Medicare Coverage for Prospera™ Organ Transplant Rejection Assessment Test
    PR Newswire

    Natera Receives Final Medicare Coverage for Prospera™ Organ Transplant Rejection Assessment Test

    Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that Medicare has finalized its local coverage determination (LCD) to provide insurance coverage for the Prospera donor-derived cell-free DNA (dd-cfDNA) test, for all kidney transplant recipients, including those with multiple kidney transplants, an expansion in coverage from the initial draft. Nearly all newly transplanted patients are eligible for Medicare coverage.

  • Hedge Funds Have Never Been This Bullish On Natera Inc (NTRA)
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On Natera Inc (NTRA)

    Like everyone else, elite investors make mistakes. Some of their top consensus picks, such as Amazon, Facebook and Alibaba, have not done well in Q4 of 2018 due to various reasons. Nevertheless, the data show elite investors' consensus picks have done well on average over the long-term. The top 20 stocks among hedge funds beat […]

  • Panorama Publication Demonstrates Utility of Measuring Individual Fetal Fractions in Twin Pregnancies
    PR Newswire

    Panorama Publication Demonstrates Utility of Measuring Individual Fetal Fractions in Twin Pregnancies

    Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced results of a study published in the Journal of Prenatal Diagnosis which demonstrated that measuring individual fetal fractions combined with reporting zygosity provides clinically powerful insights into the accuracy of the aneuploidy results.1 Panorama® remains the only non-invasive prenatal test (NIPT) that reports zygosity for twins, and individual fetal fractions for dizygotic pregnancies.2

  • What Kind Of Share Price Volatility Should You Expect For Natera, Inc. (NASDAQ:NTRA)?
    Simply Wall St.

    What Kind Of Share Price Volatility Should You Expect For Natera, Inc. (NASDAQ:NTRA)?

    If you're interested in Natera, Inc. (NASDAQ:NTRA), then you might want to consider its beta (a measure of share price...

  • Natera (NTRA) Reports Q3 Loss, Tops Revenue Estimates
    Zacks

    Natera (NTRA) Reports Q3 Loss, Tops Revenue Estimates

    Natera (NTRA) delivered earnings and revenue surprises of 0.00% and 3.80%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Natera Reports Third Quarter 2019 Financial Results
    PR Newswire

    Natera Reports Third Quarter 2019 Financial Results

    SAN CARLOS, Calif. , Nov. 6, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ:  NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today reported financial results ...

  • Natera Announces Third Quarter 2019 Earnings Conference Call
    PR Newswire

    Natera Announces Third Quarter 2019 Earnings Conference Call

    SAN CARLOS, Calif. , Oct. 30, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its third quarter ended September ...

  • Hedge Funds Are Betting On Natera Inc (NTRA)
    Insider Monkey

    Hedge Funds Are Betting On Natera Inc (NTRA)

    Based on the fact that hedge funds have collectively under-performed the market for several years, it would be easy to assume that their stock picks simply aren't very good. However, our research shows this not to be the case. In fact, when it comes to their very top picks collectively, they show a strong ability […]

  • Natera Announces Pricing of Follow-On Offering
    PR Newswire

    Natera Announces Pricing of Follow-On Offering

    SAN CARLOS, Calif. , Oct. 16, 2019 /PRNewswire/ --  Natera, Inc . (Nasdaq: NTRA), a global leader in cell-free DNA testing, today announced the pricing of its underwritten public offering of 5,714,286 ...

  • Natera Launches Proposed Follow-On Offering
    PR Newswire

    Natera Launches Proposed Follow-On Offering

    SAN CARLOS, Calif. , Oct. 15, 2019 /PRNewswire/ -- Natera, Inc . (Nasdaq: NTRA), a global leader in cell-free DNA testing, today announced the launch of a proposed follow-on public offering of $175,000,000 ...

  • Natera to Host Investor Conference Call to Discuss Progress in its Oncology Business
    PR Newswire

    Natera to Host Investor Conference Call to Discuss Progress in its Oncology Business

    SAN CARLOS, Calif. , Oct. 3, 2019 /PRNewswire/ -- Natera, Inc.  (NASDAQ: NTRA ), a global leader in cell-free DNA testing, today announced it will review recent progress in its oncology business, including ...

  • Natera (NTRA) Scales 52-Week High: What's Driving the Stock?
    Zacks

    Natera (NTRA) Scales 52-Week High: What's Driving the Stock?

    Natera (NTRA) is likely to maintain the current high on a number of favorable factors.

  • Foundation Medicine and Natera Partner to Advance Personalized Cancer Monitoring
    PR Newswire

    Foundation Medicine and Natera Partner to Advance Personalized Cancer Monitoring

    CAMBRIDGE, Mass. and SAN CARLOS, Calif., Sept. 25, 2019 /PRNewswire/ -- Foundation Medicine, Inc. and Natera, Inc. (NTRA) today announced a partnership to develop and commercialize personalized circulating tumor DNA (ctDNA) monitoring assays, for use by biopharmaceutical and clinical customers who order FoundationOne®CDx. "We are excited to develop monitoring products based on Foundation Medicine's genomic insights, and we believe that partnering with Natera, a leader in personalized ctDNA monitoring, offers the potential to significantly advance personalized medicine," said Cindy Perettie, Chief Executive Officer of Foundation Medicine. The companies will leverage Foundation Medicine's FoundationOne® CDx as the baseline test to define a set of unique variants that will subsequently be monitored utilizing a co-developed assay that includes components of Natera's Signatera™ platform.

  • PR Newswire

    CBR® Acquires Evercord™ Newborn Stem Cell Business from Natera

    LOS ANGELES , Sept. 13, 2019 /PRNewswire/ --  CBR (Cord Blood Registry), the world's largest newborn stem cell collection and storage company, today announced the asset acquisition of Natera, Inc. 's  (NASDAQ: ...

  • CBR to Acquire Natera's Evercord™ Cord Blood Business
    PR Newswire

    CBR to Acquire Natera's Evercord™ Cord Blood Business

    SAN CARLOS, Calif., Sept. 13, 2019 /PRNewswire/ -- Natera, Inc. (NTRA) and CBR (Cord Blood Registry) today announced the acquisition by CBR, a California Cryobank Life Sciences company, and the world's largest newborn stem cell collection and storage organization, of Natera's Evercord™ cord blood and tissue banking business. "This divestiture will allow Natera to focus squarely on its core genetic testing business in reproductive health, oncology and organ transplantation," said Steve Chapman, Natera's CEO.

  • Natera Publishes Largest NIPT Outcomes Study Demonstrating Robust Clinical Performance Over a 4-year Period
    PR Newswire

    Natera Publishes Largest NIPT Outcomes Study Demonstrating Robust Clinical Performance Over a 4-year Period

    SAN CARLOS, Calif., Sept. 9, 2019 /PRNewswire/ -- Natera, Inc. (NTRA), a global leader in cell-free DNA testing, today announced the publication of the largest non-invasive prenatal test (NIPT) outcomes study to date, analyzing its Panorama® assay over a 4-year period. The primary objective of the study, published in the Journal of Clinical Medicine,1 was to analyze prospectively the clinical performance of the company's NIPT as a part of its rigorous quality assurance program. Panorama now has a market-leading 19 peer-reviewed publications with 1.2 million patients, which is twice the number of patients in published studies from all other primary NIPT companies combined," said Ramesh Hariharan, General Manager of Natera's Reproductive Health business.

  • Did Natera, Inc. (NASDAQ:NTRA) Insiders Sell Shares?
    Simply Wall St.

    Did Natera, Inc. (NASDAQ:NTRA) Insiders Sell Shares?

    It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...

  • Natera to Present at the Morgan Stanley 17th Annual Global Healthcare Conference
    PR Newswire

    Natera to Present at the Morgan Stanley 17th Annual Global Healthcare Conference

    SAN CARLOS, Calif. , Sept. 4, 2019 /PRNewswire/ --  Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced it will webcast a live presentation at the Morgan Stanley 17th ...